Mutational Analysis of Prohibitin - A Highly Conserved Gene in Indian Female Breast Cancer Cases

  • Najm, Mohammad Zeeshan (Department of Biochemistry, Faculty of Science, Jamia Hamdard) ;
  • Akhtar, Md. Salman (Department of Biotechnology, Jamia Millia Islamia) ;
  • Ahmad, Istaq (Department of Biotechnology, Jamia Millia Islamia) ;
  • Sadaf, Sadaf (School of Biotechnology, Jawaharlal Nehru University New Delhi) ;
  • Mallick, Mohd Nasar (Department of Biotechnology, Jamia Millia Islamia) ;
  • Kausar, Mohd Adnan (Department of Biochemistry, Faculty of Science, Jamia Hamdard) ;
  • Chattopadhyay, Shilpi (Department of Biotechnology, Jamia Millia Islamia) ;
  • Ahad, Amjid (Department of Biochemistry, Faculty of Science, Jamia Hamdard) ;
  • Zaidi, Shuaib (Department of Surgical Oncology, Rajiv Gandhi Cancer Hospital) ;
  • Husain, Syed Akhtar (Department of Biotechnology, Jamia Millia Islamia) ;
  • Siddiqui, Waseem Ahmad (Department of Biochemistry, Faculty of Science, Jamia Hamdard)
  • Published : 2012.10.31


Prohibitin (PHB) is a chaperone protein which is highly conserved evolutionarily. It shows significant homology with the Drosophila cc gene which is considered important for development and differentiation of Drosophila melanogaster. Investigations have revealed an involvement of PHB in cellular proliferation and development, apoptosis, signal transduction, mitochondrial function and regulation of the estrogen and androgen receptors. Therefore, we conducted the present study to analyze mutations in the highly conserved region in Indian female breast cancer patients. Conventional PCR-SSCP and Automated DNA sequencing were performed with a total of 105 breast cancer samples along with adjacent normal tissue. Of the total, 14.2% (15/105) demonstrated a mutation status of prohibitin observed in our study population. We identified a novel missense mutation (Thr>Ser), a novel deletion of T nucleotide in an intron adjacent to intron-exon boundary and a previously determined missense mutation (Val>Ala). A statistically significant correlation was obtained which suggested that prohibitin may be associated with tumor development and/or progression of at least some proportion of breast cancers.


  1. Chowdhury I, Xu W, Stiles JK (2007). Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology, 148, 206-17.
  2. Coughlin SS, Ekwueme DU (2009). Breast cancer as a global health concern. Cancer epidemiol, 33, 315-8.
  3. DiRenzo J, Shang Y, Phelan M, et al (2000). BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol, 20, 7541-9.
  4. Dumitrescu RG, Cotarla I (2005), Understanding breast cancer risk - where do we stand in 2005?. J Cell Mol Med, 9, 208-21.
  5. Eveleth DD, Marsh JL (1986). Sequence and expression of Cc gene, a member of dopa decarboxylase gene cluster of Drosophila. Possible translational regulation. Nucleic Acids Res, 14, 6169-83.
  6. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008. Int J Cancer, 15, 2893-917.
  7. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S (2003). Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem, 278, 47853-61.
  8. Joshi B, Rastogi S, Morris M (2007). Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J, 401, 155-66.
  9. Julian Peto, Nadine Collins, Rita Barfoot, et al (1999). Prevalence of BRCA1 and BRCA2 Gene Mutation in Patients with Early-Onset Of Breast Cancer. J Natl Cancer Inst, 91, 943-9.
  10. Kuusisto KM, Bebel A, Vihinen M, et al (2011). Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res, 13, R20.
  11. Maillet P, Bonnefoi H, Vaudan-Vutskits G, et al (2002). Constitutional alteration of the ATM gene in early onset sporadic breast cancer. J Med Genet, 39, 751-3.
  12. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER, et al (2003). Tumor suppression by the prohibitin gene 3´ untranslated region RNA in human breast cancer. Cancer Res. 63, 5251-6
  13. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE (2001). Germ-line HER-2 Variant and Breast Cancer Risk by Stage of Disease. Cancer Res, 61, 8393-4.
  14. Nagai MA, Yamamoto L, Salaorni S, et al (1994). Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumors. Genes Chromosomes Cancer, 11, 58-62.
  15. Nuell MJ, Stewart DA, Walker L, et al (1991). Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol, 11, 1372-81.
  16. Rajalingam K, Rudel T (2005). Ras-Raf signaling needs prohibitin. Cell Cycle, 4, 1503-5.
  17. Saeki T, Tsuruo T, Sato W, Nishikawsa K (2005). Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol, 56, 84-9.
  18. Sato T, Saito H, Swensen J, et al (1992). The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res, 52, 1643-6.
  19. Sato T, Sakamoto T, Takita K, et al (1993). The human prohibitin (PHB) gene family and its somatic mutations in human tumors. Genomics, 17, 762-4.
  20. Snedden WA, Fromm H (1997). Characterization of the plant homologue of prohibitin, a gene associated with antiproliferative activity in mammalian cells. Plant Mol Biol, 33, 753-6.
  21. Vargo-Gogola T, Rosen JM (2007). Modelling breast cancer: one size does not fit all. Nat Rev Cancer, 7, 659-72.
  22. Wang S, Zhang B, Faller DV (2004). BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J, 23, 2293-303.
  23. Wang S, Nath N, Adlam M, Chellappan S (1999a). Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene, 18, 3501-10.
  24. Wang S, Nath N, Fusaro G, Chellappan S (1999b). Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol, 19, 7447-60.
  25. Zhang B, Chambers KJ, Faller DV, Wang S (2007). Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene, 26, 7153-7.

Cited by

  1. Immunohistochemical expression and mutation study of Prohibitin gene in Indian female breast cancer cases vol.30, pp.3, 2013,
  2. A novel spiroindoline targets cell cycle and migration via modulation of microtubule cytoskeleton vol.429, pp.1-2, 2017,
  3. Genetic determinants of sporadic breast cancer in Sri Lankan women vol.18, pp.1, 2018,